APOBEC3F Antikörper (AA 139-287)

Produktnummer ABIN7150156

Produktdetails anti-APOBEC3F Antikörper

Target: APOBEC3F (Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F))

Bindungsspezifität: AA 139-287

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser APOBEC3F Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (IF)

Kreuzreaktivität: Human, Maus

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human DNA dC->dU-editing enzyme APOBEC-3F protein (139-287AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: WB:1:500-1:5000, IF:1:50-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu APOBEC3F

Target: APOBEC3F (Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3F (APOBEC3F))

Andere Bezeichnung: APOBEC3F (APOBEC3F Produkte)

Synonyme: A3F antikoerper, ARP8 antikoerper, BK150C2.4.MRNA antikoerper, KA6 antikoerper, APOBEC3F antikoerper, apolipoprotein B mRNA editing enzyme catalytic subunit 3F antikoerper, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F antikoerper, APOBEC3F antikoerper

Hintergrund:

Background: DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. Exhibits antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double-stranded RNA. Exhibits antiviral activity also against hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV-related virus (XMRV) and simian foamy virus (SFV) and may inhibit the mobility of LTR and non-LTR retrotransposons. May also play a role in the epigenetic regulation of gene expression through the process of active DNA demethylation.

Aliases: A3F antibody, ABC3F_HUMAN antibody, APOBEC3F antibody, Apolipoprotein B mRNA editing enzyme, catalytic polypeptide like 3F antibody, Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3F antibody, ARP8 antibody, DNA dC->dU-editing enzyme APOBEC-3F antibody, Induced upon T cell activation antibody, KA6 antibody

UniProt: Q8IUX4